Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $11.90.

HCAT has been the topic of a number of recent research reports. Evercore ISI lifted their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Piper Sandler lowered their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Stephens reduced their target price on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. JPMorgan Chase & Co. lifted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th.

Health Catalyst Price Performance

HCAT opened at $8.25 on Thursday. The business has a 50 day moving average of $8.01 and a 200-day moving average of $7.11. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. During the same period in the prior year, the firm earned ($0.21) EPS. The business’s revenue was up 3.7% on a year-over-year basis. Equities research analysts predict that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the sale, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at $1,036,024.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12. Following the transaction, the chief operating officer now owns 134,899 shares in the company, valued at $1,036,024.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,187 shares of company stock worth $226,171. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC increased its position in Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares during the period. Impax Asset Management Group plc grew its position in shares of Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after buying an additional 360,201 shares during the period. Millennium Management LLC raised its stake in shares of Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares during the last quarter. Primecap Management Co. CA boosted its stake in Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after acquiring an additional 305,079 shares during the last quarter. Finally, Daventry Group LP boosted its stake in Health Catalyst by 3.9% in the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock valued at $14,359,000 after acquiring an additional 84,178 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.